UK – NICE backs AbbVie’s Rinvoq for severe active rheumatoid arthritis

The UK’s National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Rinvoq (upadacitinib) for people with previously treated severe active rheumatoid arthritis (RA).

NICE’s guidance recommends AbbVie’s JAK inhibitor in combination with methotrexate for people with severe active RA, if their disease has responded inadequately to, or they are intelorant to at least two conventional disease-modifying anti-rheumatic drugs.

Currently, there are around 400,000 people in the UK living with RA, an autoimmune disease wherein the immune system attacks the lining of the joints. This causes inflammation and symptoms such as pain, fatigue and stiffness…